Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Mallinckrodt
McKesson
Johnson and Johnson
Express Scripts

Last Updated: August 10, 2022

MOXIDECTIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Moxidectin patents expire, and what generic alternatives are available?

Moxidectin is a drug marketed by Mdgh and is included in one NDA.

The generic ingredient in MOXIDECTIN is moxidectin. There is one drug master file entry for this compound. Additional details are available on the moxidectin profile page.

Summary for MOXIDECTIN
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 56
Clinical Trials: 19
Patent Applications: 3,067
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in MOXIDECTIN?MOXIDECTIN excipients list
DailyMed Link:MOXIDECTIN at DailyMed
Drug patent expirations by year for MOXIDECTIN
Recent Clinical Trials for MOXIDECTIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Centre for Parasitology, Entomology and Malaria Control, CambodiaPhase 3
Public Health Laboratory Ivo de Carneri, Chake Chake, Pemba, Zanzibar, TanzaniaPhase 2/Phase 3
Public Health Laboratory Ivo de CarneriPhase 2/Phase 3

See all MOXIDECTIN clinical trials

US Patents and Regulatory Information for MOXIDECTIN

MOXIDECTIN is protected by zero US patents and two FDA Regulatory Exclusivities.

FDA Regulatory Exclusivity protecting MOXIDECTIN

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mdgh MOXIDECTIN moxidectin TABLET;ORAL 210867-001 Jun 13, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Mdgh MOXIDECTIN moxidectin TABLET;ORAL 210867-001 Jun 13, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Baxter
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.